Systematic Multi-domain Alzheimer’s Risk Reduction Trial (SMARRT): Study Protocol

Manuscript Number: 

18-0634R2

Author(s): 
Kristin J. Adams, Deborah E. Barnes, Sascha Dublin, Allison R. Kaup, Eric B. Larson, Evette J. Ludman, Carrie B. Peltz, Anne D. Renz, Dori Rosenberg, Eric Vittinghoff, Kristine Yaffe

Disclosures

Kristin J. Adams

  • Nothing to Disclose

Deborah E. Barnes

  • Grants
    • Agency: 
      Together Senior Health, Inc.
      Dates: 
      9/30/18 - 6/30/19

Sascha Dublin

  • Equity:
    I do own stocks but I do not manage my own portfolio; it is managed by a financial advisor who has been instructed to avoid pharmaceutical and healthcare stocks.
    Grants
    • Agency: 
      Jazz Pharmaceuticals
      Dates: 
      2/1/2018-5/30/2019

Allison R. Kaup

  • Consulting Fees:
    Scientific advisor for Squint Metrics

Eric B. Larson

  • Consulting Fees:
    UpToDate - evidence-based, clinical decision support resource.

Evette J. Ludman

  • Nothing to Disclose

Carrie B. Peltz

  • Nothing to Disclose

Anne D. Renz

  • Nothing to Disclose

Dori Rosenberg

  • Nothing to Disclose

Eric Vittinghoff

  • Equity:
    Equities: CVS Health $30,067 Johnson & Johnson $23,896 Merck, $1082 Novo Nordisk $24,379 Other equities in non-health related companies: $430,082

Kristine Yaffe

  • Consulting Fees:
    I serve on several DSMBs for both the NIH and industry. None have any content overlap or conflict with this manuscript or protocol.